Last reviewed · How we verify
Keratoconjunctivitis sicca
Approved treatments
- Sandimmune · Novartis
- Sandimmune · Novartis AG (originally Sandoz)
Calcineurin inhibitor that suppresses T-cell activation by blocking IL-2 transcription, preventing organ transplant rejection. - ciclosporine · Hospices Civils de Lyon
- Neoral · Novartis Pharmaceuticals
- Cyclosporin · Karolinska University Hospital
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Keratoconjunctivitis sicca patent landscape — cliff calendar, originator estates, attackable patents
- Keratoconjunctivitis sicca treatment landscape brief
- Keratoconjunctivitis sicca treatment updates RSS
Frequently asked questions about Keratoconjunctivitis sicca
What drugs treat Keratoconjunctivitis sicca?
Tracked treatments include Sandimmune, ciclosporine, Neoral, Cyclosporin.
What is the treatment for Keratoconjunctivitis sicca?
Standard treatment for Keratoconjunctivitis sicca includes Sandimmune, ciclosporine, Neoral, Cyclosporin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Keratoconjunctivitis sicca patent cliff · Keratoconjunctivitis sicca CI report
- Treatment: Sandimmune · Novartis
- Treatment: Sandimmune · Novartis AG (originally Sandoz)
- Treatment: ciclosporine · Hospices Civils de Lyon
- Treatment: Neoral · Novartis Pharmaceuticals
- Treatment: Cyclosporin · Karolinska University Hospital
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing